2016 VAM: 2809 - Novel Biologicals for Asthma and Allergic Rhinosinusitis
This session will aim to inform about two major therapeutic strategies, namely biologicals and allergen-speciffic immunothrapy for asthma and allergic rhinits and their mechanisms of action. Allergen-specific immunotherapy, aims to induce specific immune tolerance and has a long-term disease-modifying effect. The second approach is the use of biological immune response modifiers to decrease pathological immune responses targeting a dominant inflammatory mechanism, such as IgE, IL-5, IL-13.
AMA PRA Category 1 Credits™: 1.25
Credit must be claimed by May 31, 2018. Any credit request on or after June 1, 2018 will be subject to an administrative fee.
Allied Health Professionals
Upon completion of this activity, participants will be able to:
1. Discuss novel biologicals in allergy and immunology
2. Discuss mechanisms underlying novel immunologic therapies
Prof. Cezmi A. Akdis, MD FAAAAI, Swiss Institute of Allergy and Asthma Research, Davos, Switzerland
Prof. Claus Bachert, MD PhD, Upper Airway Research Laboratory (URL), Ghent University Hospital, Ghent, Belgium
Dr. Sally E. Wenzel, MD FAAAAI, University of Pittsburgh Medical Center NW, Pittsburgh, PA
- 1.25 AttendanceAttendance credit.
- 1.25 CECE credit.
- 1.25 CMECME credit.